Drug intelligence / Profile preview

[18F]F-PTTP

Development stage: Preclinical
Modality: Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

[18F]F-PTTP is a novel fluorine-18 (18F) labeled radioligand designed for Positron Emission Tomography (PET) imaging. It is synthesized through a 1-step 18F-trifluoromethylation reaction. This radiopharmaceutical specifically targets and binds to the P2X purinoceptor 7 (P2X7R), a purinergic receptor involved in inflammatory processes. Its primary application is in the visualization of P2X7R expression, offering potential for imaging inflammation, distinguishing inflammatory conditions from certain solid tumors, and serving as a tool for screening new drugs and quantifying peripheral inflammation.

Targets

P2RX7 (P2X purinoceptor 7)

Beyond the preview

Go deeper on [18F]F-PTTP.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on [18F]F-PTTP.

Explore the full profile